{"entity":{"id":"nct05887492","kind":"trial","name":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Tango Therapeutics, Inc., active and no longer recruiting.","summary":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors is a phase 1/2 interventional study registered as NCT05887492 by Tango Therapeutics, Inc., with 126 participants planned, started 2023-06-12 and due to reach its primary completion in 2026-09. Interventions recorded: TNG260, Pembrolizumab. Conditions listed: Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05887492","url":"https://clinicaltrials.gov/study/NCT05887492"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","tng260"],"companies":["tango-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05887492","phase":"1/2","setting":"A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors","sponsor":"Tango Therapeutics, Inc.","participation":[{"nct":"NCT05887492","source":"https://clinicaltrials.gov/study/NCT05887492","fetchedAt":"2026-10-07T16:53:59.307Z","studySha256":"d46d36413342f11fe9e19d3e0dcf2a01da0e456b87d0e4d53df9b55a9d359a0f","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-07-06","leadSponsor":"Tango Therapeutics, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":126,"enrolmentType":"ESTIMATED","siteCount":13,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2023-06-12","startedType":"actual","enrolled":126,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05887492/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"tng260","kind":"drug","name":"TNG260","route":"/drugs/tng260/"}],"company":[{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/"}],"target":[{"id":"stk11","kind":"target","name":"STK11","route":"/targets/stk11/"}]}}